by John Conrad | Nov 5, 2024 | Policy News
Disclaimer: iBIO is a nonpartisan organization and does not endorse any candidate for public office. This article is provided for informational purposes only to help our members understand potential policy implications of election outcomes. As voters head to the polls...
by John Conrad | Sep 19, 2024 | NewsBrief
Syntax Bio has launched with $15 million in funding from notable investors, including Astellas Venture Management LLC and Illumina Ventures. The Chicago-based startup is pioneering a novel approach to cell therapy with its Cellgorithm platform. Syntax Bio’s...
by John Conrad | Jul 29, 2024 | iBIO in the News
GEN Releases 2024 Top Biopharma Clusters: Chicago Climbs to 9th Place Genetic Engineering & Biotechnology News (GEN) has unveiled its annual list of top biopharma clusters for 2024, with Chicago making a notable ascent in the rankings. The Windy City has moved up...
by John Conrad | Jul 25, 2024 | iBIO News
We’re trying something new! Welcome to the first NewsBrief Innovation Insider Interview, where we chat with leaders from the biotech, pharma, medtech, venture capital and science community and explore cutting-edge ideas and strategies to help you gain actionable...
by John Conrad | Jul 24, 2024 | NewsBrief
The University of Chicago’s Polsky Center for Entrepreneurship and Innovation has forged a strategic partnership with Orange Grove Bio (OGB), an integrated biopharmaceutical company, in a move set to accelerate biotech innovation and commercialization. This...
